We think that the identification of this specific CSC subpopulation and its association with gemcitabine resistance has significant clinical implications: targeting the ARPC1B+ CSC subpopulation may serve as an effective strategy to overcome the chemoresistance of pancreatic cancer cells to gemcitabine. Here, ARPC1B is linked to familial pancreatic carcinoma.